BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Trikudanathan G, Venkatesh PG, Navaneethan U. Diagnosis and therapeutic management of extra-intestinal manifestations of inflammatory bowel disease. Drugs. 2012;72:2333-2349. [PMID: 23181971 DOI: 10.2165/11638120-000000000-00000] [Cited by in Crossref: 50] [Cited by in F6Publishing: 45] [Article Influence: 5.6] [Reference Citation Analysis]
Number Citing Articles
1 Olesen MTJ, Ballarín-gonzález B, Howard KA. The application of RNAi-based treatments for inflammatory bowel disease. Drug Deliv and Transl Res 2014;4:4-18. [DOI: 10.1007/s13346-013-0156-9] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
2 Buchbender M, Fehlhofer J, Proff P, Möst T, Ries J, Hannig M, Neurath MF, Gund M, Atreya R, Kesting M. Expression of inflammatory mediators in biofilm samples and clinical association in inflammatory bowel disease patients-a preliminary study. Clin Oral Investig 2021. [PMID: 34383142 DOI: 10.1007/s00784-021-04093-2] [Reference Citation Analysis]
3 Noble A, Durant L, Hoyles L, Mccartney AL, Man R, Segal J, Costello SP, Hendy P, Reddi D, Bouri S, Lim DNF, Pring T, O'Connor MJ, Datt P, Wilson A, Arebi N, Akbar A, Hart AL, Carding SR, Knight SC. Deficient Resident Memory T Cell and CD8 T Cell Response to Commensals in Inflammatory Bowel Disease. J Crohns Colitis 2020;14:525-37. [PMID: 31665283 DOI: 10.1093/ecco-jcc/jjz175] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 17.0] [Reference Citation Analysis]
4 Ribaldone DG, Brigo S, Mangia M, Saracco GM, Astegiano M, Pellicano R. Oral Manifestations of Inflammatory Bowel Disease and the Role of Non-Invasive Surrogate Markers of Disease Activity. Medicines (Basel) 2020;7:E33. [PMID: 32560118 DOI: 10.3390/medicines7060033] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
5 Greuter T, Navarini A, Vavricka SR. Skin Manifestations of Inflammatory Bowel Disease. Clinic Rev Allerg Immunol 2017;53:413-27. [DOI: 10.1007/s12016-017-8617-4] [Cited by in Crossref: 46] [Cited by in F6Publishing: 29] [Article Influence: 9.2] [Reference Citation Analysis]
6 Sheth T, Pitchumoni CS, Das KM. Musculoskeletal manifestations in inflammatory bowel disease: a revisit in search of immunopathophysiological mechanisms. J Clin Gastroenterol. 2014;48:308-317. [PMID: 24492406 DOI: 10.1097/mcg.0000000000000067] [Cited by in Crossref: 24] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
7 Zhao H, Zhao L, Shi W, Luo H, Duan L, You Y, Li Y, Zuo X. Is it bowel-associated dermatosis-arthritis syndrome induced by small intestinal bacteria overgrowth? Springerplus 2016;5:1551. [PMID: 27652124 DOI: 10.1186/s40064-016-3236-8] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
8 Hagen JW, Swoger JM, Grandinetti LM. Cutaneous manifestations of crohn disease. Dermatol Clin. 2015;33:417-431. [PMID: 26143422 DOI: 10.1016/j.det.2015.03.007] [Cited by in Crossref: 37] [Cited by in F6Publishing: 26] [Article Influence: 6.2] [Reference Citation Analysis]
9 Falling C, Stebbings S, Baxter GD, Mani R. Central hypersensitivity - A model for persistent musculoskeletal pain in inflammatory bowel diseases. Med Hypotheses 2019;129:109243. [PMID: 31371091 DOI: 10.1016/j.mehy.2019.109243] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
10 Falling C, Stebbings S, Baxter GD, Siegel CA, Gearry RB, Nijs J, Mani R. Symptoms of central sensitization in patients with inflammatory bowel diseases: a case-control study examining the role of musculoskeletal pain and psychological factors. Scand J Pain 2021;21:283-95. [PMID: 34387957 DOI: 10.1515/sjpain-2020-0109] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
11 Yamamoto-Furusho JK, Sánchez-Morales GE. Factors Associated with the Presence of Extraintestinal Manifestations in Patients with Ulcerative Colitis in a Latin American Country. Inflamm Intest Dis 2020;5:200-4. [PMID: 33313072 DOI: 10.1159/000510070] [Reference Citation Analysis]
12 Brandse JF, Vos LM, Jansen J, Schakel T, Ponsioen CI, van den Brink GR, D'Haens GR, Löwenberg M. Serum Concentration of Anti-TNF Antibodies, Adverse Effects and Quality of Life in Patients with Inflammatory Bowel Disease in Remission on Maintenance Treatment. J Crohns Colitis. 2015;9:973-981. [PMID: 26116557 DOI: 10.1093/ecco-jcc/jjv116] [Cited by in Crossref: 26] [Cited by in F6Publishing: 28] [Article Influence: 3.7] [Reference Citation Analysis]
13 Katsanos KH, Torres J, Roda G, Brygo A, Delaporte E, Colombel JF. Review article: non-malignant oral manifestations in inflammatory bowel diseases. Aliment Pharmacol Ther. 2015;42:40-60. [PMID: 25917394 DOI: 10.1111/apt.13217] [Cited by in Crossref: 31] [Cited by in F6Publishing: 25] [Article Influence: 4.4] [Reference Citation Analysis]
14 Li X, Shen J, Ran Z. Crosstalk between the gut and the liver via susceptibility loci: Novel advances in inflammatory bowel disease and autoimmune liver disease. Clinical Immunology 2017;175:115-23. [DOI: 10.1016/j.clim.2016.10.006] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
15 Jang HJ, Kang B, Choe BH. The difference in extraintestinal manifestations of inflammatory bowel disease for children and adults. Transl Pediatr 2019;8:4-15. [PMID: 30881893 DOI: 10.21037/tp.2019.01.06] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
16 Park KS. Lung injury as an extra-intestinal manifestation of inflammatory bowel disease. Korean J Intern Med 2016;31:851-2. [PMID: 27604797 DOI: 10.3904/kjim.2016.266] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
17 Navaneethan U. Hepatobiliary manifestations of ulcerative colitis: an example of gut-liver crosstalk. Gastroenterol Rep (Oxf). 2014;2:193-200. [PMID: 24951514 DOI: 10.1093/gastro/gou036] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 1.9] [Reference Citation Analysis]
18 Chams S, Badran R, Sayegh SE, Chams N, Shams A, Hajj Hussein I. Inflammatory bowel disease: Looking beyond the tract. Int J Immunopathol Pharmacol 2019;33:2058738419866567. [PMID: 31382828 DOI: 10.1177/2058738419866567] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 5.5] [Reference Citation Analysis]
19 Anderson A, Ferris LK, Click B, Ramos-Rivers C, Koutroubakis IE, Hashash JG, Dunn M, Barrie A, Schwartz M, Regueiro M, Binion DG. Low Rates of Dermatologic Care and Skin Cancer Screening Among Inflammatory Bowel Disease Patients. Dig Dis Sci. 2018;63:2729-2739. [PMID: 29713987 DOI: 10.1007/s10620-018-5056-x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 1.8] [Reference Citation Analysis]
20 Lankarani KB, Sivandzadeh GR, Hassanpour S. Oral manifestation in inflammatory bowel disease: A review. World J Gastroenterol 2013; 19(46): 8571-8579 [PMID: 24379574 DOI: 10.3748/wjg.v19.i46.8571] [Cited by in CrossRef: 88] [Cited by in F6Publishing: 61] [Article Influence: 9.8] [Reference Citation Analysis]
21 Vavricka SR, Schoepfer A, Scharl M, Lakatos PL, Navarini A, Rogler G. Extraintestinal Manifestations of Inflammatory Bowel Disease. Inflamm Bowel Dis. 2015;21:1982-1992. [PMID: 26154136 DOI: 10.1097/mib.0000000000000392] [Cited by in Crossref: 256] [Cited by in F6Publishing: 103] [Article Influence: 42.7] [Reference Citation Analysis]
22 Falling C, Stebbings S, Baxter GD, Gearry RB, Mani R. Musculoskeletal Pain in Individuals With Inflammatory Bowel Disease Reflects Three Distinct Profiles. The Clinical Journal of Pain 2019;35:559-68. [DOI: 10.1097/ajp.0000000000000698] [Cited by in Crossref: 8] [Cited by in F6Publishing: 1] [Article Influence: 2.7] [Reference Citation Analysis]
23 Rogler G, Singh A, Kavanaugh A, Rubin DT. Extraintestinal Manifestations of Inflammatory Bowel Disease: Current Concepts, Treatment, and Implications for Disease Management. Gastroenterology 2021:S0016-5085(21)03337-0. [PMID: 34358489 DOI: 10.1053/j.gastro.2021.07.042] [Reference Citation Analysis]
24 Wang X, Shen B. Management of Crohn’s Disease and Complications in Patients With Ostomies. Inflammatory Bowel Diseases 2018;24:1167-84. [DOI: 10.1093/ibd/izy025] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
25 Xu W, Ou W, Guo Y, Gu Y, Cui L, Zhong J, Du P. Clinical outcomes and risk factors of secondary extraintestinal manifestation in ulcerative colitis: results of a multicenter and long-term follow-up retrospective study. PeerJ 2019;7:e7194. [PMID: 31304061 DOI: 10.7717/peerj.7194] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
26 Sange AH, Srinivas N, Sarnaik MK, Modi S, Pisipati Y, Vaidya S, Syed Gaggatur N, Sange I. Extra-Intestinal Manifestations of Inflammatory Bowel Disease. Cureus 2021;13:e17187. [PMID: 34548984 DOI: 10.7759/cureus.17187] [Reference Citation Analysis]
27 Vlachos C, Gaitanis G, Katsanos KH, Christodoulou DK, Tsianos E, Bassukas ID. Psoriasis and inflammatory bowel disease: links and risks. Psoriasis (Auckl) 2016;6:73-92. [PMID: 29387596 DOI: 10.2147/PTT.S85194] [Cited by in Crossref: 4] [Cited by in F6Publishing: 11] [Article Influence: 0.7] [Reference Citation Analysis]
28 Vannala V, Palaian S, Shankar PR. Therapeutic Dimensions of Bisphosphonates: A Clinical Update. Int J Prev Med 2020;11:166. [PMID: 33312475 DOI: 10.4103/ijpvm.IJPVM_33_19] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
29 King D, Chandan JS, Thomas T, Nirantharakumar K, Reulen RC, Adderley NJ, Trudgill N. The Risk of Later Diagnosis of Inflammatory Bowel Disease in Patients With Dermatological Disorders Associated With Inflammatory Bowel Disease. Inflamm Bowel Dis 2021;27:1731-9. [PMID: 34669933 DOI: 10.1093/ibd/izaa344] [Reference Citation Analysis]
30 Majewski S, Piotrowski W. Pulmonary manifestations of inflammatory bowel disease. Arch Med Sci. 2015;11:1179-1188. [PMID: 26788078 DOI: 10.5114/aoms.2015.56343] [Cited by in Crossref: 30] [Cited by in F6Publishing: 20] [Article Influence: 4.3] [Reference Citation Analysis]
31 Kröner PT, Lee A, Farraye FA. Respiratory Tract Manifestations of Inflammatory Bowel Disease. Inflamm Bowel Dis 2021;27:563-74. [PMID: 32448912 DOI: 10.1093/ibd/izaa112] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
32 Sartini A, Bianchini M, Schepis F, Marzi L, De Maria N, Villa E. Complete resolution of non-necrotizing lung granuloma and pyoderma gangrenosum after restorative proctocolectomy in a woman with severe ulcerative colitis and cytomegalovirus infection. Clin Case Rep 2016;4:195-202. [PMID: 26862424 DOI: 10.1002/ccr3.464] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
33 Li X, Lu C, Yang Y, Yu C, Rao Y. Site-specific targeted drug delivery systems for the treatment of inflammatory bowel disease. Biomed Pharmacother 2020;129:110486. [PMID: 32768972 DOI: 10.1016/j.biopha.2020.110486] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 4.5] [Reference Citation Analysis]
34 Defilippis E, Feldman S, Huang W. The genetics of pyoderma gangrenosum and implications for treatment: a systematic review. Br J Dermatol 2015;172:1487-97. [DOI: 10.1111/bjd.13493] [Cited by in Crossref: 57] [Cited by in F6Publishing: 40] [Article Influence: 8.1] [Reference Citation Analysis]
35 Zhang XL, Li YF, Zhou P. Extraintestinal manifestations of inflammatory bowel disease and their treatment strategies. Shijie Huaren Xiaohua Zazhi 2016; 24(6): 894-901 [DOI: 10.11569/wcjd.v24.i6.894] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
36 Ott C, Schölmerich J. Extraintestinal manifestations and complications in IBD. Nat Rev Gastroenterol Hepatol. 2013;10:585-595. [PMID: 23835489 DOI: 10.1038/nrgastro.2013.117] [Cited by in Crossref: 124] [Cited by in F6Publishing: 115] [Article Influence: 13.8] [Reference Citation Analysis]
37 Garber A, Regueiro M. Extraintestinal Manifestations of Inflammatory Bowel Disease: Epidemiology, Etiopathogenesis, and Management. Curr Gastroenterol Rep. 2019;21:31. [PMID: 31098819 DOI: 10.1007/s11894-019-0698-1] [Cited by in Crossref: 21] [Cited by in F6Publishing: 12] [Article Influence: 7.0] [Reference Citation Analysis]
38 Roth N, Biedermann L, Fournier N, Butter M, Vavricka SR, Navarini AA, Rogler G, Scharl M; Swiss IBD Cohort Study Group. Occurrence of skin manifestations in patients of the Swiss Inflammatory Bowel Disease Cohort Study. PLoS One 2019;14:e0210436. [PMID: 30682031 DOI: 10.1371/journal.pone.0210436] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
39 Vasovic M, Gajovic N, Brajkovic D, Jovanovic M, Zdravkovaic N, Kanjevac T. The relationship between the immune system and oral manifestations of inflammatory bowel disease: a review. Cent Eur J Immunol. 2016;41:302-310. [PMID: 27833449 DOI: 10.5114/ceji.2016.63131] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 2.8] [Reference Citation Analysis]
40 Coman RM, Glover SC, Gjymishka A. Febrile pleuropericarditis, a potentially life-threatening adverse event of balsalazide – case report and literature review of the side effects of 5-aminosalicylates. Expert Review of Clinical Immunology 2014;10:667-75. [DOI: 10.1586/1744666x.2014.902313] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
41 Perez-alamino R, Maldonado-ficco H, Maldonado-cocco JA. Rheumatic manifestations in inflammatory bowel diseases: a link between GI and rheumatology. Clin Rheumatol 2016;35:291-6. [DOI: 10.1007/s10067-015-3116-6] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 1.1] [Reference Citation Analysis]
42 Nir O, Rinawi F, Amarilyo G, Harel L, Shamir R, Assa A. Phenotypic Features and Longterm Outcomes of Pediatric Inflammatory Bowel Disease Patients with Arthritis and Arthralgia. J Rheumatol 2017;44:1636-43. [PMID: 28864649 DOI: 10.3899/jrheum.170168] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
43 Di Ruscio M, Tinazzi I, Variola A, Geccherle A, Marchetta A, McGonagle D. Prevalence and Real-World Management of Vedolizumab Associated Enthesitis in Successfully Treated IBD Patients. Rheumatology (Oxford) 2021:keab135. [PMID: 33580246 DOI: 10.1093/rheumatology/keab135] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
44 Falling C, Stebbings S, Baxter GD, Gearry RB, Mani R. Profile of musculoskeletal pain in patients with inflammatory bowel disease: a study protocol for assessing the multidimensional experience of self-reported pain. Physical Therapy Reviews 2018;23:227-35. [DOI: 10.1080/10833196.2018.1500149] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
45 Brown SR, Coviello LC. Extraintestinal Manifestations Associated with Inflammatory Bowel Disease. Surg Clin North Am. 2015;95:1245-159, vii. [PMID: 26596925 DOI: 10.1016/j.suc.2015.08.002] [Cited by in Crossref: 20] [Cited by in F6Publishing: 12] [Article Influence: 3.3] [Reference Citation Analysis]
46 Bijelić B, Matić IZ, Besu I, Janković L, Juranić Z, Marušić S, Andrejević S. Celiac disease-specific and inflammatory bowel disease-related antibodies in patients with recurrent aphthous stomatitis. Immunobiology 2019;224:75-9. [DOI: 10.1016/j.imbio.2018.10.006] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
47 Dubinsky MC, Cross RK, Sandborn WJ, Long M, Song X, Shi N, Ding Y, Eichner S, Pappalardo B, Ganguli A, Wang A. Extraintestinal Manifestations in Vedolizumab and Anti-TNF-Treated Patients With Inflammatory Bowel Disease. Inflamm Bowel Dis. 2018;. [PMID: 29668916 DOI: 10.1093/ibd/izy065] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 13.5] [Reference Citation Analysis]
48 Núñez F P, Quera P R, Gomollón F. Primary sclerosing cholangitis and inflammatory bowel disease: Intestine-liver interrelation. Gastroenterol Hepatol 2019;42:316-25. [PMID: 30948141 DOI: 10.1016/j.gastrohep.2019.02.004] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
49 Greuter T, Vavricka SR. Extraintestinal manifestations in inflammatory bowel disease – epidemiology, genetics, and pathogenesis. Expert Review of Gastroenterology & Hepatology 2019;13:307-17. [DOI: 10.1080/17474124.2019.1574569] [Cited by in Crossref: 30] [Cited by in F6Publishing: 22] [Article Influence: 10.0] [Reference Citation Analysis]